Sight Sciences, Inc.·Healthcare

Sight Sciences, Inc. (NASDAQ: SGHT - Get Free Report) EVP Brenton Taylor sold 2,869 shares of the stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $3.70, for a total value of $10,615.30. Following the completion of the sale, the executive vice president directly owned 267,807

Sight Sciences, Inc. (NASDAQ: SGHT - Get Free Report) CTO David Badawi sold 8,168 shares of Sight Sciences stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $3.48, for a total transaction of $28,424.64. Following the transaction, the chief technology officer directly owned 1,990,290 shares in

Sight Sciences, Inc. (NASDAQ: SGHT - Get Free Report) CEO Paul Badawi sold 29,244 shares of Sight Sciences stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $3.70, for a total value of $108,202.80. Following the sale, the chief executive officer directly owned 6,151,156 shares in the company,

MENLO PARK, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced that data on two of its proprietary glaucoma and dry eye technologies, the OMNI® Surgical System and the TearCare® System, will be presented at this year's ASCRS Annual Meeting held in Washington, DC.

MENLO PARK, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced plans to present at the 25th Annual Needham Healthcare Conference being held virtually.

Court preserves jury's finding of willful infringement by Alcon, and awards past damages to Sight Sciences in excess of $34 million and ongoing royalties through November 2028 Court preserves jury's finding of willful infringement by Alcon, and awards past damages to Sight Sciences in excess of $34 million and ongoing royalties through November 2028
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Healthcare
Medical - Devices
216
2021-07-15
2.49